Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY 3375968 |
Synonyms | |
Therapy Description |
BAY 3375968 is an anti-CCR8 monoclonal antibody, which potentially reduces CCR8-positive regulatory T-cells in the tumor microenvironment through antibody dependent cellular cytotoxicity (ADCC) and cellular phagocytosis (ADCP) (Cancer Res 2022;82(12_Suppl):Abstract nr 2866). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY 3375968 | BAY3375968|BAY-3375968 | CCR8 Antibody 9 | BAY 3375968 is an anti-CCR8 monoclonal antibody, which potentially reduces CCR8-positive regulatory T-cells in the tumor microenvironment through antibody dependent cellular cytotoxicity (ADCC) and cellular phagocytosis (ADCP) (Cancer Res 2022;82(12_Suppl):Abstract nr 2866). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05537740 | Phase I | BAY 3375968 + Pembrolizumab BAY 3375968 | A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | BEL | 2 |